<DOC>
	<DOCNO>NCT02397863</DOCNO>
	<brief_summary>This open-label , multi-center study open patient 1 18 year age time enrollment medication resistant epilepsy .</brief_summary>
	<brief_title>Epidiolex Drug Resistant Epilepsy Children</brief_title>
	<detailed_description>This open-label , multi-center study open patient 1 18 year age time enrollment medication resistant epilepsy . The study consist 8 week baseline , titration , treatment Epidiolex daily dosage 25 mg/kg/day , optional secondary titration schedule 26 week treatment maximal daily dosage 50 m/kg/day End Treatment , follow taper-down period , safety follow . Treatment provide total 52 week interim analysis conduct 12 week achieve maximal dose ( either 25 mg/kg/day optimal dose regard safety tolerability ) end 1 year treatment treatment extension conduct beyond 52 week time market authorization Epidiolex , Epidiolex become unavailable , study terminate . Cessation Epidiolex administration conclude taper period follow-up visit 4 week taper .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>Patient history try least four antiepileptic drug ( AEDs ) , include one trial combination two concomitant drug , without successful seizure control . Vagal nerve stimulation , RNS deep brain stimulation , ketogenic diet consider equivalent drug trial . Patient must take two AEDs dose stable least four week . A State Georgia resident . Patient diagnose Dravet Syndrome LennoxGastaut Syndrome eligible GW PharmaceuticalSponsored Clinical Trial . Patients part clinical trial involve another investigational product previous six month .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>